Basis: Trailing twelve months (TTM). Source: stored company filings and market data; unavailable inputs remain N/A.
The enterprise value (EV) is $466.04M.
ENTERPRISE VALUE (EV)
$466.04M
Allogene Therapeutics, Inc.
Market Cap
$517.73M
Enterprise Value (EV)
$466.04M
| NAME | MARKET CAP | ENTERPRISE VALUE (EV) |
|---|---|---|
| Allogene Therapeutics, Inc. (ALLO) | $517.73M | $466.04M |
| Crescent Biopharma, Inc. (CBIO)vs › | $517.79M | $347.63M |
| Altimmune, Inc. (ALT)vs › | $519.25M | $491.94M |
| Evolus, Inc. (EOLS)vs › | $491.93M | $611.57M |
| NeoGenomics, Inc. (NEO)vs › | $491.55M | $794.37M |
| Delcath Systems, Inc. (DCTH)vs › | $547.86M | $502.80M |
| Bright Minds Biosciences Inc. (DRUG)vs › | $487.30M | $270.40M |
| Immix Biopharma, Inc. (IMMX)vs › | $551.09M | $326.60M |
| Arvinas, Inc. (ARVN)vs › | $481.33M | $395.23M |
| Contineum Therapeutics, Inc. (CTNM)vs › | $478.54M | $470.40M |
Market Cap
$517.73M
Total Debt
$0.00
Cash
$51.69M
Enterprise Value
$466.04M
Why use EV instead of Market Cap?
Enterprise Value represents the total value of a company as if you were to acquire it completely - paying for equity while assuming debt and receiving cash.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
